Genzyme gets rights to Alnylam's RNAi candidates for ATTR; rights expanded in new deal
RNAi therapeutics developer Alnylam Pharmaceuticals Inc. has granted Sanofi’s Genzyme Corp. exclusive rights to develop and sell two of its candidates targeting transthyretin (TTR; a protein normally produced by the liver) to treat transthyretin-mediated amyloidosis (ATTR). Sanofi’s rights cover Japan and other Asia-Pacific countries, including Korea, Taiwan, China, India, Australia, and New Zealand.
- Antisense, Oligonucleotides
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com